More on REGN

- Summary
- Chart
- Profile
- Historical


- Earnings (+16.2% Growth)
- Ratings (6.1 Score)
- Holders
- FDA Archive


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (8/5/22 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

REGN Balance Sheet

Click line-items for a historical chart and %
Current assets
Cash and cash equivalents 920.36M
Marketable securities 488.03M
Accounts receivable from Sanofi
Accounts receivable - other 1.33B
Prepaid expenses and other current assets 103.81M
Total current assets 3.5B
Restricted cash and marketable securities
Marketable securities 777.91M
Property, plant, and equipment, at cost, net of accumulated depreciation and amortization 1.87B
Other assets 20.71M
Total assets 6.83B
Current liabilities
Accounts payable and accrued expenses 714.92M
Deferred revenue from Sanofi, current portion 105.04M
Deferred revenue - other, current portion 137.64M
Facility lease obligations, current portion
Total current liabilities 961.19M
Deferred revenue from Sanofi 529.79M
Deferred revenue - other 327.87M
Facility lease obligations 382.23M
Other long term liabilities 135.7M
Total liabilities 2.34B
Commitments and contingencies
Stockholders' equity
Preferred stock 0
Common Stock 2K
Additional paid-in capital 3.31B
Accumulated deficit 1.5B
Accumulated other comprehensive loss -2.9M
Total stockholders' equity 4.49B
Total liabilities and stockholders' equity 6.83B
Class A Stock [Member]
Stockholders' equity
Common Stock 107K